1. Background
2. Objectives
3. Methods
3.1. Bacterial Strains and Plasmids
3.2. Genetic Features of the DNA Regions Surrounding blaNDM-1
| Primer | Sequence (5’→3’) |
|---|---|
| F1 | TGTATAGCGCGGGAGTACAC |
| F2 | CGAGCATTACCAAAGGGTGA |
| F3 | GGTAAGTGGCTTTCAGGTGC |
| F4 | CCAGCTCGCACCGAATGTCT |
| F5 | CCGCGAAAATCAAGATTTGC |
| F6 | TCGACGCAGGTAAGACACTT |
| R1 | GTTGCCAAGATACAGAGCCG |
| R2 | TGGTCGCTGGATTAACTGGT |
| R3 | CCGCAACCATCCCCTCTT |
| R4 | GCGACGCTGGATAGAACACC |
| R5 | ACTGACGCAAAATCAAC |
| R6 | AGTATGGCGGTATGGAGGTG |
| R7 | TGCAACGACACAGAGCTAAC |
3.3. Construction of the Knockout Mutant
| Primer | Sequence (5’→3’) |
|---|---|
| Ftet | ATCGATCGTTCTCATGTTTGACAGCTTATC |
| Rtet | ATCGATCGTCAGGTCGAGGTGGCCCGGCT |
| PN1 | TGCGGGTAAGGATTTCAGGC |
| PN2 | TGACAGCATCATCCGCATCG |
| PZ1 | ATCGCCGGGAGAATGCTTTATC |
| PZ2 | CGATTCCGAACCGTGCAGCT |
| PD1 | AGCTCGGCACCGAATGTCT |
| PD2 | CCGCAACCATCCCCTCTT |
| FropB | AAGGCGAATCCAGCTTGTTCAGC |
| RropB | TGACGTTGCATGTTCGCACCCATCA(12) |
aNucleotides indicated by underlining are restriction sites
3.4. Antimicrobial Susceptibility
3.5. Growth Curves and in vitro Competition Experiments
3.6. Statistical Methods
4. Results
4.1. Genetic Features of the blaNDM-1 Gene
Comparison of the sequences surrounding the blaNDM-1 gene. (A) blaNDM-1-surrounding sequences in A.baumannii 161/07 (accession no. HQ857107), A. lwoffii pNDM-Bj01 (accession no. JQ001791); (B and E) blaNDM-1-surrounding sequences in E. coli pNDM-HK (accession no. HQ451074) and E. coli DVR22 (accession no. JF922606). (C and D) blaNDM-1-surrounding sequences identified in this study, E. cloacae T1-T9 and E. cloacae T10. The boxed arrows indicate the positions and directions of gene transcription. Δ represents truncated genes.
4.2. Construction of the blaNDM-1 Knockout Mutant in E. cloacaeT2
Construction of the blaNDM-1 knockout mutant. (A) M: Middle DNA Marker I; lane 1: PCR amplification of pKD46-Tet using the primers Ftet/Rtet; lanes 2~3: Digestion of pKD46-Tet using Pvui. (B) M:DL5000 DNA Marker; lanes 1~6: PCR amplification of the homologous recombination fragments using the primers PN1/PN2. (C) M: DL5000 DNA Marker; lanes 1~5: PCR amplification of the positive colonies (T2 Δ NDM-1::Kn); lanes 6: PCR amplification of the original strain. (D) M:DL2000 DNA Marker; lanes 1~4: PCR amplification of the blaNDM-1 knockout mutant (T2 Δ NDM-1); lane 5: PCR amplification of the positive colonies (T2 Δ NDM-1::Kn).
4.3. Antimicrobial Susceptibility Patterns
| Isolate No. | VITEK2 | Etest | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PIP | TET | ATM | CRO | CIP | AMK | MEM | IPM | ETP | TGC | MEM | IMP | ETP | |
| E. cloacae T2 | ≥ 128 | 4 | ≥ 64 | ≥ 64 | ≥ 4 | ≤ 2 | ≥ 16 | ≥ 16 | ≥ 8 | 1 | > 32 | > 32 | > 32 |
| T2 Δ NDM-1 | ≥ 128 | 4 | ≥ 64 | ≥ 64 | ≥ 4 | ≤ 2 | ≤ 0.25 | ≤ 1 | ≤ 0.5 | 1 | 0.125 | 0.38 | 0.125 |
| ATCC25922 | ≤ 4 | ≤ 1 | ≤ 1 | ≤ 1 | ≤ 0.25 | ≤ 2 | ≤ 0.25 | ≤ 1 | ≤ 0.5 | ≤ 0.5 | 0.032 | 0.019 | 0.008 |
Abbreviations: AMK, amikacin; ATM, aztreonam; CIP, ciprofloxacin; CRO, Ceftriaxone; ETP, ertapenem; IPM, imipenem; MEM, meropenem; PIP, piperacillin; TET, tetracycline; TGC, tigecycline


